AACR Meeting II 2020 Participation

Presentations/Educational Sessions

Circulating Tumor DNA for Patient Stratification
_A multi-gene prostate cancer liquid biopsy with > 92% accuracy in diagnosis and assessment of disease status_
Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Pawel Rajwa, Christof Bernemann, Lisa Bodei, _Irvin Modlin_
Session: June 23; 10:05 AM

The Evolving Role of the Pathologist in Cancer Research
_High-dimensional imaging technologies in pathology diagnosis and cancer research_
Author: David L. Rimm
Abstract: 3
Session: June 23; 12:45 PM

Clinical Trial Design: Part 2: Clinical Trials Issues with Molecularly Targeted Agents
_Incorporating translational research into clinical trials of targeted agents_
Author: Katerina A. Politi
Session: June 23; 1:15 PM

Cancer Increases in Younger Populations: Where Are They Coming from?
_Early-onset colorectal cancer_
Author: Xavier Llor
Session: June 23; 1:45 PM

Dharma Master Jiantai Symposium in Biomarkers: High-Dimensional Imaging of Immune and Tumor Cells in Human FFPE Tissue
_Understanding the immune composition of human lung cancer using multiparametric and spatially resolved tissue analysis_
Author: Kurt Alex Schalper
Session: June 23; 4:00 PM

Cancer Immunity
_3424 - IL-18 immunotherapy is efficacious against checkpoint-immunotherapy refractory tumors by promoting the maturation of highly proliferative, polyfunctional NK cells_
Clinical Trial Design: Part 3: Clinical Development of IO Agents
Combination strategies with IO agents
Author: Roy S. Herbst
Session: June 24; 2:15 PM

Posters

Mechanisms of Sensitivity and Resistance to Targeted Therapy 3
Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment
Authors: Michal Marczyk, Vignesh Gunasekharan, Jun Zhao, Rihao Qu, Xiaotong Li, Gauri A. Patwardhan, Vikram B. Wali, Abhishek K. Gupta, Manoj M. Pillai, Yuval Kluger, Christos Hatzis, B
Abstract: 6333
Poster: 16
Session: June 22; 9:00 AM

Immune Response to Therapies 1
VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer
Authors: Alicia Ding, Franz Villarroel-Espindola, Adam Ducler, Brian S. Henick, Shruti Desai, Nicole Gianino, Jon Zugazagoitia, David L. Rimm, Alain Robert, Francisco Cruzalegui, Pierre Ferré, Roy Herbst, Miguel Sanmamed, Lieping Chen, Kurt A. Schalper
Abstract: 5525
Poster: 15
Session: June 22; 9:00 AM

Novel Antitumor Agents 2
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma
Authors: Elena Bonazzoli, Stefania Bellone, Luca Zammataro, Barbara Gnotti, Adele Guglielmi, Silvia Pelligr, Paola Manara, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Alessandro D. Santin
Abstract: 5341
Poster: 30
Session: June 22; 9:00 AM

Immune Cells in the Tumor Microenvironment 4
Comparison of tumor immune microenvironment in triple negative breast cancer (TNBC) of African American versus that of white patients
Authors: Vesal Yaghoobi, Vasiliki Pelekanou, Tess O’Meara, Andrea Silber, Lajos Puszta, David Rimm, Kim Blenman
Abstract: 4973
Poster: 8
Session: June 22; 9:00 AM

Mechanisms of Drug Action 1
Combination of the Aurora A inhibitor TAS-119 and adavosertib results in synergistic c-Jun-mediated cell death in head and neck and lung cancers
Authors: Jong Woo Lee, Cindy Yang, Barbara Burtness
Abstract: 604
Poster: 1
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1
Diagnostic utility of the NETest in neuroendocrine transformed prostate cancer
Authors: Kambiz Rahbar, Mark Kidd, Ignat Drozdov, Alexandra Kitz, Anna Malczewska, Lisa Bodei, Pawel Rajwa, Christof Bernemann, Irvin Modlin
Abstract: 1999
Poster: 7
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1
Biomarker discovery in immunotherapy-treated melanoma patients with imaging mass cytometry
Authors: Sandra Martinez-Morilla, Franz Villarroel-Espindola, Pok Fai Wong, Harriet Kluger, Maria Toki, Thazin New Aung, Vasiiki Pelekanou, Brian Bourke-Martín, David L. Rimm
Abstract: 2001
Poster: 9
Session: June 22; 9:00 AM

Predictive Biomarkers for Treatment Efficacy 1
Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC
Authors: Yuting Liu, Jon Zugazagoitia, Kurt A. Schalper, Roy S. Herbst, David L. Rimm
Abstract: 2002
Poster: 10
Session: June 22; 9:00 AM

Adaptive Immunity to Tumors
IL-18 pathway agonism expands intratumoral PD1+ Tcf1+ stem-like CD8+ cells and their polyfunctional effector progeny to promote anti-tumor immunity
Authors: Ting Zhou, Orr-El Weizman, William Damsky, Meaghan McGearly, Marcus W. Bosenberg, Aaron M. Ring
Abstract: 2156
Poster: 17
Session: June 22; 9:00 AM

Mechanisms of DNA Damaging Therapeutics
Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib
Authors: Christopher Hong, Amrita Sule, Jason Beckta, Ranjini Sundaram, Ranjit Bindra
Abstract: 1389
Poster: 25
Session: June 22; 9:00 AM

Circulating Markers 3
Combination of spatial protein data with bulk transcriptional profiling of the same cohort shows relationships between RNA and protein and facilitates combined predictive signatures
Authors: Ioannis A. Vathiotis, Jason Reeves, Maria Toki, Pok Fai Wong, Harriet Kluger, Thazin Nwe Aung, Konstantinos N. Syrigos, Sarah Warren, David L. Rimm
Abstract: 3095
Poster: 5
Session: June 22; 9:00 AM

**Immune Checkpoints 1**
Quantitative assessment of CD200 and CD200R expression in lung cancer
Authors: Ioannis A. Vathiotis, Tyler MacNeil, Jon Zugazagoitia, Sandra Martinez-Morilla, Fahad Ahmed, Konstantinos N. Syrigos, Aaron M. Gruver, Kyla Driscoll, David L. Rimm
Abstract: 937
Poster: 20
Session: June 22; 9:00 AM

Mechanisms of Resistance and Sensitivity to EGFR Targeting
Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 (FGFR1) via MAPK pathway
Authors: Yuhong Lu, Yanfeng Liu, Sebastian Oeck, Gary J. Zhang, Peter M. Glazer
Abstract: 1877
Poster: 21
Session: June 22; 9:00 AM

Preclinical Advances and Novel Cell Cycle Targets
Combination of letrozole plus abemaciclib is synergistic and suppresses tumor growth in ovarian and endometrial cancer models
Authors: Zhigui Li, Jing Ji, Gloria S. Huang
Abstract: 4851
Poster: 13
Session: June 22; 9:00 AM

Innovative Assay Technologies
Novel seroprofiling assay reveals previously undescribed autoantibody responses in immunotherapy treated cancer patients
Authors: Connor E. Rosen, Yile Dai, Miguel F. Sanmamed, Aaron M. Ring
Abstract: 6292
Poster: 5
Session: June 22; 9:00 AM

New Imaging-based Approaches to Plan, Monitor, and Augment Cancer Treatment
Mapping the extracellular pH gradient of colorectal cancer after immuno-thermal ablation
Authors: Daniel Coman, Johannes M. Ludwig, Hyun S. Kim
Abstract: 2778
Poster: 10
Session: June 22; 9:00 AM

Obesity, Physical Activity, and Related Biomarkers
Do obese patients present with worse breast cancer?
Authors: Julian Huang, Anees Chagpar
Signaling through Growth Factor Receptors, Kinases, and Phosphatases in Cancer

**PPP6C regulation of ERK signaling in melanoma**
Authors: **Hua Jane Lou, Benjamin E. Turk**
Abstract: 3754
Poster: 21
Session: June 22; 9:00 AM

Modulation of DNA Repair, New Nonclinical Models for Targets, and Other Targets

**Characterization of ATRX loss combined with IDH1 R132H mutation in gliomas**
Authors: **Ranjit Bindra, Ryan Jensen**
Abstract: 4134
Poster: 25
Session: June 22; 9:00 AM

Model Organisms for Cancer Research

**Role of aldehyde dehydrogenase 1B1 in colon carcinogenesis in a newly developed mouse model**
Authors: Wan Ying Tan, David. J. Orlicky, Ying Chen, Yatrik M. Shah, David C. Thompson, **Vasillis Vasiliou**
Abstract: 6141
Poster: 21
Session: June 22; 9:00 AM

Phase I Clinical Trials

**An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort**
Authors: **Patricia LoRusso**, Javier García-Corbacho, Fadi S. Braiteh, Anthony Gonçalves, Francesco Ricci, Hiroji Iwata, Marta Capelán, Marie Paule Sablin, Aleix Prat, Molly Catherine Hardebeck, Marta Puig, Dennis Chin-Lun Huang, Mingchi Hsu, Douglas Yee
Abstract: CT165
Poster: 21
Session: June 22; 9:00 AM

Late-Breaking Research: Clinical Research 2

**Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis**
Authors: **Barbara Burtness**, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto De Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona Swaby, Burak Gumuscu, Kevin Harrington
Abstract: LB-258
Poster: 2
Session: June 22; 9:00 AM

Epigenetic Targets

**Prodigiosin inhibits the proliferation and migration of mcf-7 breast cancer cells through the demethylation of mir-200c gene**
Mathematical Modeling

A computational model for the PI3K/Akt/mTOR pathway predicts PTEN as a negative feedback loop
Authors: Radha Mukherjee, Neal Rosen, Andre Levchenko
Abstract: 5506
Poster: 24
Session: June 22; 9:00 AM

Genomics and Genetic Susceptibility

Genome-wide interaction scan identifies gene by smoking interaction at 2q21.3 for pancreatic cancer risk
Authors: Evelina Mocci, William Wheeler, Laufey T. Amundadottir, Donghui Li, Eric J. Jacobs, Gloria M. Petersen, Brian M. Wolpin, Harvey A. Risch, Peter Kraft, Nilanjan Chatterjee, Alison P. Klein, Rachael Z. Stolzenberg-Solomon
Abstract: 1213
Poster: 21
Session: June 22; 9:00 AM

Gene and Vector-Based Therapy

Development of MAEGI as a new class of immune gene therapy for cancer treatment
Author: Sidi Chen
Abstract: 4070
Poster: 19
Session: June 22; 9:00 AM

Phase I Clinical Trials

A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors
Authors: Patricia LoRusso, Ani Balmanoukian, Sam Klempner, D R. Camidge, Matthew Hellmann, Michael Gordon, Johanna Bendell, Lars Mueller, Rachel Sabado, Patrick Twomey, Leila Delamarre, Jack Huang, Mahesh Yadav, Jingbin Zhang, Patrick McDonald, Felicitas Müller, Evelyina Derhovanessian, Özlem Türeci, Ugur Sahin, Lillian Siu
Abstract: CT-169
Session: June 22; 9:00 AM

Late-Breaking Research: Clinical Research 2

Efficacy and safety of AB928 plus modified FOLFOX-6 (mFOLFOX-6) in participants with metastatic colorectal cancer (mCRC): Initial results at the recommended dose for expansion (ARC-3)
Authors: Michael Cecchini, Manuel Modiano, Fadi Braiteh, Olivia S. Gardner, Houston N. Gilbert, Daniel DiRenzo, Lisa Seitz, Matt J. Walters, Fangfang Yin, Rachel Woloski, Melissa C. Paoloni, Ki Y. Chung
Abstract: LB-387
Poster: 11
Session: June 22; 9:00 AM